| Literature DB >> 35095694 |
Sofía García-Sanjuán1, Manuel Fernández-Alcántara2, Violeta Clement-Carbonell2, Concepción Petra Campos-Calderón3, Núria Orts-Beneito4, María José Cabañero-Martínez1.
Abstract
Introduction: Congruence, understood as the agreement between the patient's preferred place of death and their actual place of death, is emerging as one of the main variables indicating the quality of end-of-life care. The aim of this research was to conduct a systematic literature review on levels and determinants of congruence in palliative patients over the period 2010-2021. Method: A systematic review of the literature in the databases of PubMed, Scopus, Web of Science, PsycINFO, CINAHL, Cuiden, the Cochrane Library, CSIC Indexes, and IBECS. Information was extracted on research characteristics, congruence, and associated factors.Entities:
Keywords: congruence; end of life; hospital; palliative care; patient preference; place of death; systematic review
Year: 2022 PMID: 35095694 PMCID: PMC8792401 DOI: 10.3389/fpsyg.2021.807869
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Study characteristics.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| 1. Sheridan et al. ( | ROS | 12 | 963 | P | 43 | 75.8 | Cancer: 100 | 20 |
| 2. Cai et al. ( | POS | 26 | 290 | P, CG | P: 53.8 | P: 72.4 (12.38) | Cancer: 100 | 21 |
| CG: 67.2 | CG: 59.3 (13.10) | |||||||
| 3. Skorstengaard et al. ( | RCT | 36 | N: 205 | P | 50 | 69 (NI) | Cancer: 50.1 | 21 |
| n (intervention) 102 | Heart disease: 16.7 | |||||||
| n (control): 103 | Lung disease: 33.2 | |||||||
| 4. Ali et al. ( | ROS | 60 | 2176 | P | NI | NI | Cancer: 88 | 18 |
| Non-cancer: 22 | ||||||||
| 5. Blanchard et al. ( | ROS | 22 | 191 | P | 55.5 | 57.6 (13.26) | Cancer: 100 | 19 |
| 6. Wiggins et al. ( | ROS | 16 | 1047 | P | 64.6 | <79 (DT 13.8) | Cancer: 10.0 | 19 |
| Cardiac disease: 4.4 | ||||||||
| Vascular disease: 2.2 | ||||||||
| Respiratory disease: 1.7 | ||||||||
| Neurological disease: 1.6 | ||||||||
| Dementia: 75.8 | ||||||||
| Other: 4.3 | ||||||||
| 7. Bannon et al. ( | ROS | 6 | 467 (363 included in the analysis) | P | 60.6 | <69 (57.5%) | Cancer: 100 | 18 |
| 8. Chiba et al. ( | Mixed | 12 | 18 P/CG | P, CG, GP | P: 11.2 | P: 71.9 (12.4) | Cancer: 100 | 18 |
| 24 GP | CG: 94.4 | CG: 61.9 (12.9) | ||||||
| GP: 16.7 | GP: NI | |||||||
| 9. Raijmakers et al. ( | ROS | 17 | 797 | P | P: 53.6 | P <65 57.6% | Cancer: 43.7 | 19 |
| CG: 69.3 | CG <75 27.2% | Stroke: 12.4 | ||||||
| COPD: 10.9 | ||||||||
| Heart failure: 14.6 | ||||||||
| Dementia: 26.5 | ||||||||
| 10. Higginson et al. ( | POS | 17 | 138 | P | 49 | 74 (NI) | Cancer: 88.0 | 18 |
| Non-cancer: 12.0 | ||||||||
| 11. Lin et al. ( | ROS | 55 | 481 | P | 39.3 | 70.6 (14.3) | Cancer: 70.9 | 21 |
| Non-cancer: 29.1 | ||||||||
| 12. Howell et al. ( | ROS | 36 | 323 | P | 44.9 | 72.4 (12.7) | Cancer (haematological): 100 | 21 |
| 13. de Graaf et al. ( | ROS | 6 | 130 | P | 52 | 72 (12.1) | Cancer: 89 | 21 |
| Lung failure, COPD: 3 | ||||||||
| Renal failure: 1 | ||||||||
| ALS: 2 | ||||||||
| Heart failure: 1 | ||||||||
| Dementia: 1 | ||||||||
| Other: 2 | ||||||||
| 14. Arnold et al. ( | ROS | 12 | 1127 | P | 50 | 70 (13) | Cancer: 94 | 15 |
| Other: 6 | ||||||||
| 15. Burge et al. ( | ROS | 24 | 1316 (605 included in the analysis) | P | 51.3 | 79.1 (12.8) | Cancer: 38.1 | 21 |
| 16. Gage et al. ( | ROS | 18 | 688 | P | 43.6 | 75.10 (NI) | NI | 18 |
| 17. Ko et al. ( | ROS | 36 | 695 | P | 43,3 | ≥ 65: 67.9% | Cancer: 100 | 19 |
| 18. Hunt et al. ( | ROS | 7 | 1422 | P, CG | P: 34.6 | P: ≥ 60: 91.8% | Cancer: 34.6 | 20 |
| CG: 64.9 | CG: ≥ 60: 55.5% | Cardiovascular disease: 24.9 | ||||||
| Other: 40.5 | ||||||||
| 19. Aoun and Skett ( | POS | 18 | 43 (36 included in the analysis) | P | 49 | 74 (10.1) | Cancer: 100 | 20 |
| 20. Brogaard et al. ( | POS | 21 | 96 | P | 41.7 | 69.9 (NI) | Cancer: 100 | 20 |
| 21. Fischer et al. ( | POS | 29 | 458 | P | 35 | 57.9 (14.8) | Cancer: 11 | 18 |
| Other: 89 | ||||||||
| 22. Janssen et al. ( | POS | 24 | 265 (206 included in the analysis) | P | 35.9 | 67.2 (13.1) | COPD: 41.8 | 21 |
| Chronic heart failure: 29.6 | ||||||||
| Chronic renal failure: 28.6 | ||||||||
| 23. Capel et al. ( | POS | 24 | 788 | P | NI | NI | Cancer: 93 | 21 |
| Non-cancer: 7 | ||||||||
| 24. Johnson et al. ( | POS | 15 | 126 (80 included in the analysis) | P | 38 | 78 (10.7) | Chronic heart failure: 100 | 21 |
| 25. Abarshi et al. ( | ROS | 12 | 252 (165 included in the analysis) | P | 55 | > 65: 80% | Cancer: 38 | 20 |
| Non-cancer: 62 | ||||||||
| 26. Alonso-Babarro et al. ( | POS | 36 | 380 (228 included in the analysis) | P, CG | P: 39.5 | P: 66.76 (13.4) | Cancer: 100 | 20 |
| CG: 17.9 | CG: 54,32 (14.4) | |||||||
| 27. Escobar Pinzon et al. ( | CS | 4 | 1378 | P, CG | P:55.6 | P: 77.6 (13.2) | Cancer: 24.2 | 21 |
| CG: 63.4 | CG: 58.8 (12.8) | Dementia: 8.9 | ||||||
| Cardiovascular disease: 8.4 | ||||||||
| Other: 12.0 | ||||||||
| Multimorbidity: 36.6 | ||||||||
| Missing/I don't know: 9.9 | ||||||||
| 28. Gerrard et al. ( | ROS | 2007: 6 | n (2007): 236 | P | 2007: 50.5 | 2007: 78 (NI) | 2007: Cancer: 66 | 20 |
| 2009: 6 | n (2009): 275 | Other: 34 | ||||||
| Total: 511 | 2009: 42.0 | 2009: 72 (NI) | 2009: Cancer: 76 | |||||
| Other: 24 | ||||||||
| 29. Walker et al. ( | ROS | 24 | 150 | P | NI | NI | NI | 19 |
| 30. Holdsworth and Fisher ( | ROS | 6 | 298 | P | NI | NI | Cancer: 80 | 18 |
| Other: 20 |
RCT, randomised controlled trial; ROS, retrospective observational study; POS, prospective observational study; CS, cross-sectional study; COPD, chronic obstructive pulmonary disease; ALS, amyotrophic lateral sclerosis; NI, no information; RRS, rapid response service; P, patient; CG, caregivers; GP, general practitioners.
Results on preferred place, final place of death, congruence, and the existence of associated factors.
|
|
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| ||||
| 1. Sheridan et al. ( | 17.7 | 40.6 | 14.1 | 18.1 | 58.0 | 20.0 | 11.0 | 10.2 | 66.1% | NI | PREF |
| 2. Cai et al. ( | 16.9 | 65.5 | 1.4 | 16.2 | 29.3 | 48.6 | 1.4 | 20.7 | 71.7% | 1-2-3 | TOT |
| K: 0.527 | |||||||||||
| 3. Skorstengaard et al. ( | GI: 1.0 | GI: 33.5 | GI: 3.9 | GI: 2.9 | GI: 17.3 | GI: 42.3 | GI: 0.0 | GI: 34.6 | GI: 52.4% | NI | TOT |
| GC: 1.0 | GC: 34 | GC: 2.9 | GC: 4.9 | GC: 27.1 | GC: 17.0 | GC: 8.5 | GC: 32.2 | GC: 34.6% | |||
| 4. Ali et al. ( | 1.2 | 44.8 | 5.5 | 12.0 | 21.2 | 46.5 | 8.4 | 23.8 | 69% | NI | PREF |
| 5. Blanchard et al. ( | – | 54.5 | – | – | – | 40.3 | – | – | 47.6% | 1-2 | TOT |
| K: 0.016 | |||||||||||
| IC 95%: (−0.107)−0.139 | |||||||||||
| 6. Wiggins et al. ( | 0.4 | 31.1 | 49.8 | 1.4 | 12.1 | 26.5 | 50.9 | 3.2 | 83.7% | 1-2 | TOT |
| 7. Bannon et al. ( | 3.5 | 74.7 | 1.7 | 6.0 | 43.7 | 38.1 | 9.0 | 9.2 | Home: 53.4% | 1-2-3 | TOT |
| 8. Chiba et al. ( | 11.1 | 61.1 | – | – | 11.1 | 88.9 | – | – | 100% | NI | TOT |
| 9. Raijmakers et al. ( | 1.8 | 65.7 | 24.3 | 8.3 | – | – | – | – | 69.0% | 1-2-3 | TOT |
| 10. Higginson et al. ( | 4.0 | 56.0 | 2.0 | 22.0 | 34.0 | 21.0 | 6.0 | 39.0 | 23.0% | NI | TOT |
| 11. Lin et al. ( | – | 49.1 | – | 49.9 | – | 42.8 | – | 57.2 | 92.3% | 2-3 | TOT |
| 12. Howell et al. ( | 28.2 | 45.8 | 5.6 | 16.9 | 74.3 | 15.2 | 5.0 | 5.6 | 63.4% | NI | TOT |
| 13. de Graaf et al. ( | – | 72.0 | – | 21.0 | 6.0 | 70.0 | – | 24.0 | 86% | NI | TOT |
| 14. Arnold et al. ( | 0.7 | 37.0 | 2.4 | 60.0 | – | – | – | – | 85% | NI | PREF |
| 15. Burge et al. ( | 15.9 | 73.9 | 10.3 | – | 51.5 | 30.4 | 17.9 | – | 51.9% | NI | PREF |
| K: 0.29 | |||||||||||
| 16. Gage et al. ( | 2-3 | TOT | |||||||||
| 17. Ko et al. ( | – | 100 | – | – | 16.7 | 76.0 | 1.3 | 6.0 | 76.0% | 2-3 | TOT |
| 18. Hunt et al. ( | 5.1 | 73.9 | 6.5 | 10.6 | 49.4 | 13.4 | 24.6 | 10.5 | 49.3% | NI | TOT |
| K: 0.034 | |||||||||||
| 19. Aoun and Skett ( | 8.0 | 56.0 | – | 25.0 | 22.0 | 14.0 | – | 56.0 | 41.2% | NI | PREF |
| 20. Brogaard et al. ( | 3.0 | 45.0 | 1.0 | 16.0 | 26.0 | 41.0 | 6.0 | 26.0 | 44.0% | NI | TOT |
| 21. Fischer et al. ( | 10.0 | 75.0 | 6.0 | 4.0 | 35.0 | 31.0 | 20.0 | 12.0 | 37.0% | 2 | TOT |
| 22. Janssen et al. ( | 33.3 | 51.5 | – | – | 57.5 | 27.3 | – | – | 39.4% | NI | TOT |
| K: 0.07 | |||||||||||
| 23. Capel et al. ( | 1.7 | 48.2 | 5.2 | 14.4 | 30.0 | 36.0 | 6.3 | 27.1 | Home: 69% | NI | TOT |
| Hospital: 85.7% | |||||||||||
| Long-term: 82.9% | |||||||||||
| Hospice: 81.6% | |||||||||||
| 24. Johnson et al. ( | – | – | 61% | NI | PREF | ||||||
| 25. Abarshi et al. ( | – | – | – | – | 28.6 | 43.7 | 21.4 | 6.3 | No deaths identified in recent days: 21% | NI | PREF |
| Deaths identified in recent days 79% | |||||||||||
| 26. Alonso-Babarro et al. ( | – | 80 | – | – | – | 72.4 | – | – | 89% | NI | PREF |
| 27. Escobar Pinzon et al. ( | 0.4 | 50.5 | 1.3 | 1.5 | 39.3 | 38.2 | 13.4 | 7.5 | 58.9% | 2-3 | PREF |
| K: 0.14 | |||||||||||
| 28. Gerrard et al. ( | +9.0 | +44.0 | +11.0 | +36.0 | – | – | – | – | 76.0% | NI | PREF |
| ++31.0 | ++24.0 | ++7.0 | ++38.0 | ||||||||
| 29. Walker et al. ( | – | 78.6 | – | 21.4 | 27.0 | 35.0 | 11.0 | 27.0 | 85.7% | NI | PREF |
| 30. Holdsworth and Fisher ( | 0.7 | 26.8 | 1.3 | 9.7 | 17.8 | 36.6 | 8.4 | 37.2 | 61.7% | NI | TOT |
| K: 0.38 | |||||||||||
K, kappa; 95% CI, 95% confidence interval for cohen's kappa; GI, group intervention; CG, control group; NI, no information; PREF, calculated on those showing a preference; TOT, calculated on the total sample;
users rapid response service;
non-users rapid response services; +2007 data; ++2009 data; 1: illness-related factors, 2: individual factors, 3: environmental factors.
Factors associated with congruence between preferred and final place of death.
|
|
| ||
|---|---|---|---|
|
|
|
| |
| Cai et al. ( | • Patient functional status- | • Civil status (divorced, separated or widowed) - OR: 0.45; IC 95%: 0.36–0.56 | • Intensity of home-based nursing visits+ |
| Blanchard et al. ( | • Use of morphine + | • Aged + OR: 1.03; IC 95%: 1.00–1.05 | |
| Wiggins et al. ( | • Patient functional status (impairment) + | • Cardiopulmonary resuscitation preference- OR: 0.32; IC 95%: 0.16–0.62 | |
| Bannon et al. ( | • Being unconscious during final week of life - | • Discussing POD with a HCP + OR: 4.7; IC 95%: 1.9–11.5 | • Living in an affluent area + |
| Raijmakers et al. ( | • Dementia diagnosis | • Having a partner+ OR: 2.03; IC 95%: 1.23–3.35 | • Have had contact with a general practitioner in the last week before death + |
| Lin et al. ( | • PPOD Inpatient Hospice + OR: 17.37; IC 95%: 5.13–58.82 | • Use of a High Intensity Hospice information system (HIS) + | |
| Gage et al. ( | • Declare an initial PPOD Care Home + OR: 7.7; IC 95%: 2.5–23.4 | • User of RRS+ | |
| Ko et al. ( | • Aged (65-85) + OR (Belgium): OR: 0.4; IC 95%: 0.2–0.97 | • GP provision of palliative care + | |
| Fischer et al. ( | • Female + OR: 3.30; IC 95%: 1.25–8.72 | ||
| Escobar Pinzon et al. ( | • Having a non-working relative + OR: 1.79; IC 95%: 1.16–2.76 | • Living in a rural municipality + | |
+, positive association between the variables; -, inverse association between the variables; POD, place of death; PPOD, preferred place of death; HCP, health care professionals; GP, general practitioners; RRS, rapid response service.
Figure 1Flow diagram of the selection of studies for the systematic review. Source: Moher et al. (2009).
Summary of the factors affecting congruence.
|
|
|
|---|---|
|
|
|
| Patient's functional status | Patient's functional status |
| Dementia | Cancer |
| Treatment-related aspects | Stroke |
| Patient's level of consciousness during last days | |
|
|
|
| Marital status | Preference for dying at home |
| Non-working relative | Preference for cardiopulmonary resuscitation |
| Age | Early registering of place of death |
| Preference for dying in a hospice | Being female |
| Having spoken to a healthcare professional about the preferred place of death | Religious beliefs |
| Decision-making capacity | |
| Being female | |
|
|
|
| Place of residence | Place of residence |
| Indicators of adequate care | Time of participation in the study |
| Family role | |
| Caregiver's preference | |
| High intensity hospice | |
| Having palliative care |